newsfilter
← Latest News
GlobeNewswire·

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists